Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28588874 | 0.98 | RBP4 (0.33) | RBP4FFAR3CYP4F2CYP4A11DGAT1 | |
| SCHEMBL4742520 | 0.91 | CYP4F2 (0.31) | FFAR3CYP4F2CYP4A11DGAT1 | |
| SCHEMBL4829842 | 0.91 | NPSR1 (0.31) | FFAR3CYP4F2CYP4A11DGAT1 | |
| SCHEMBL23293553 | 0.90 | CYP2C19 (0.32) | FFAR3CYP4F2CYP4A11 | |
| SCHEMBL7884001 | 0.88 | CYP2C19 (0.31) | CYP4F2CYP4A11 | |
| SCHEMBL2146137 | 0.88 | OPRM1 (0.34) | CYP4F2CYP4A11 | |
| SCHEMBL5360795 | 0.86 | USP2 (0.41) | USP2SMN1; SMN2 | |
| SCHEMBL7978037 | 0.83 | BTK (0.30) | — | |
| SCHEMBL80613 | 0.82 | DGAT1 (0.37) | CYP4F2CYP4A11DGAT1USP2SMN1; SMN2 | |
| SCHEMBL1087991 | 0.81 | MAPK1 (0.31) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116178154-B | Preparation method of fullerene ester derivative | 湖北大学 | 2025-04-11 | — | — | CN | disclosed |
| EP-4440700-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-09 | — | — | EP | disclosed |
| CN-118355020-A | Therapeutic compounds for HIV virus infection | 吉利德科学公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023102529-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11357755-B2 | Compounds for controlling arthropods | BAYER ANIMAL HEALTH GMBH (DE) | 2022-06-14 | — | — | US | disclosed |
| EP-4003963-A1 | PYRAZOLE DERIVATIVES FOR CONTROLLING ARTHROPODS | Bayer Animal Health GmbH (DE) | 2022-06-01 | — | — | EP | disclosed |
| CN-114423740-A | Pyrazole derivatives for controlling arthropods | 拜耳动物保健有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-8729095-B2 | 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20120245152-A1 | 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2471792-A1 | 3-(BIARYLOXY) PROPIONIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-5605925-A | COGNITION ACTIVATOR; ALZHEIMER'S DISEASE | HOECHST MARION ROUSSEL, INC. (US) | 1997-02-25 | — | — | US | disclosed |
| US-5580987-A | TREATING 1-PHTHALIMIDOPYRROLE WITH BASE TO YIELD 1-AMINOPYRROLE, REACTING WITH SUBSTITUTED AMINO ACID TO OBTAIN DESIRED COMPOUND | HOECHST MARION ROUSSEL, INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5576446-A | GLYCINE PARTIAL AGONIST AND ENHANCEMENT OF LEARNING AND MEMORY, TREATMENT OF ALZHEIMER'S | HOECHST MARION ROUSSEL, INC. (US) | 1996-11-19 | — | — | US | disclosed |
| US-5428053-A | Treats alzheimer's disease and other senile dementias | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0582182-A1 | 1-Aminoacetamidopyrroles and 1-amino-2-(substituted) pyrroles and their use for the treatment of neurodegenerative dysfunctions | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-02-09 | — | — | EP | disclosed |
| US-5274116-A | 1-aminoacetamidopyrroles and 1-aminoacetamido-2-(substituted)pyrroles and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | RBP4 4480/4885FFAR3 3006/4885CYP4F2 1640/4885 |
| US-20120245152-A1 | 3-(BIARYOXY)PROPIONIC ACID DERIVATIVE | F11, PF4, F2 | RBP4 816/4885FFAR3 21/4885CYP4F2 2229/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | RBP4 4480/4885FFAR3 3006/4885CYP4F2 1640/4885 |
| US-11357755-B2 | Compounds for controlling arthropods | DDT, AAAS, AGO2 | RBP4 566/4885FFAR3 2701/4885CYP4F2 19/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RBP4 3608/4885FFAR3 4209/4885CYP4F2 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.